OptimizeRx Corp Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
5analysts covering
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 5 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Average revenue per top 20 pharmaceutical manufacturers Quarterly2.8M
Net revenue retention Quarterly1.1
Percent of total revenue attributable to top 20 pharmaceutical manufacturers Quarterly0.5
Revenue per average full-time employee Quarterly801K
Watch Items
- Most Favored Nation (MFN) pricing dynamics and macroeconomic headwindsTrigger: Further downward revision of FY2026 revenue guidance below $95 millionAction: Re-evaluate cost structure and accelerate the transition to programmatic DSP integrations to offset direct pharma budget cuts
- Transition to subscription-based and programmatic revenue modelsTrigger: Programmatic EHR network inventory utilization rate or DAAP subscription run-rate stalling below 10%Action: Increase direct sales outreach to mid-tier and emerging biopharma clients and expand DSP partnerships
Research as of 20 Jun 2026